Top

Published in:

01-04-2014 | Research Article

The association between RASSF1A promoter methylation and prostate cancer: evidence from 19 published studies

Authors: Yu-Zheng Ge, Lu-Wei Xu, Rui-Peng Jia, Zheng Xu, Yu-Ming Feng, Ran Wu, Peng Yu, Yan Zhao, Zan-Long Gui, Si-Jia Tan, Qun Song

Published in: Tumor Biology | Issue 4/2014

Abstract

Ras-associated domain family 1A (RASSF1A) is a putative tumor suppressor gene located at 3p21.3, and the epigenetic inactivation of RASSF1A by hypermethylation of CpG islands within the promoter region has been observed in various cancer types, including prostate cancer (PCa). However, results from published studies on the association between RASSF1A promoter methylation and PCa risk are conflicting and inconclusive. Hence, we conducted a meta-analysis of 19 eligible studies with odds ratio (OR) and its corresponding 95% confidence intervals (95% CI) in order to investigate the strength of relationship of RASSF1A promoter methylation with PCa risk and its clinicopathological variables. Overall, the RASSF1A promoter methylation was significantly associated with PCa risk (OR = 9.58, 95% CI 5.64–16.88, P heterogeneity <0.001) and Gleason score (GS) (OR = 2.58, 95% CI 1.64–4.04, P heterogeneity = 0.019). In addition, subgroup analysis by testing material demonstrated the significant association between RASSF1A methylation and GS (OR = 3.09, 95% CI 1.92–4.97, P heterogeneity =0.042), PSA level (OR = 2.75, 95% CI 1.67–4.52, P heterogeneity = 0.639), and tumor stage (OR = 1.74, 95% CI 1.05–2.87, P heterogeneity = 0.026) in tissue rather than urine samples. In conclusion, this meta-analysis suggested that RASSF1A promoter methylation was significantly associated with an increased risk for PCa; furthermore, the RASSF1A methylation status in tissue rather than urine was positively correlated with GS, serum PSA level, and tumor stage, which can be utilized for the early detection and prognosis prediction of PCa.

Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30. doi:10.3322/caac.21166.PubMedCrossRef

Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991;324(17):1156–61. doi:10.1056/NEJM199104253241702.PubMedCrossRef

Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol. 2010;28(1):126–31. doi:10.1200/JCO.2009.24.2180.PubMedCrossRef

Andriole GL, Crawford ED, Grubb 3rd RL, Buys SS, Chia D, Church TR, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360(13):1310–9. doi:10.1056/NEJMoa0810696.PubMedCentralPubMedCrossRef

Suva ML, Riggi N, Bernstein BE. Epigenetic reprogramming in cancer. Science. 2013;339(6127):1567–70. doi:10.1126/science.1230184.PubMedCrossRef

Bastian PJ, Yegnasubramanian S, Palapattu GS, Rogers CG, Lin X, De Marzo AM, et al. Molecular biomarker in prostate cancer: the role of CpG island hypermethylation. Eur Urol. 2004;46(6):698–708. doi:10.1016/j.eururo.2004.07.022.PubMedCrossRef

Van Neste L, Herman JG, Otto G, Bigley JW, Epstein JI, Van Criekinge W. The epigenetic promise for prostate cancer diagnosis. Prostate. 2012;72(11):1248–61. doi:10.1002/pros.22459.PubMedCrossRef

Jeronimo C, Bastian PJ, Bjartell A, Carbone GM, Catto JW, Clark SJ, et al. Epigenetics in prostate cancer: biologic and clinical relevance. Eur Urol. 2011;60(4):753–66. doi:10.1016/j.eururo.2011.06.035.PubMedCrossRef

Agathanggelou A, Cooper WN, Latif F. Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res. 2005;65(9):3497–508. doi:10.1158/0008-5472.CAN-04-4088.PubMedCrossRef

10.

Hesson LB, Cooper WN, Latif F. The role of RASSF1A methylation in cancer. Dis Markers. 2007;23(1–2):73–87.PubMedCentralPubMedCrossRef

11.

Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet. 2000;25(3):315–9. doi:10.1038/77083.PubMedCrossRef

12.

Maruyama R, Toyooka S, Toyooka KO, Virmani AK, Zochbauer-Muller S, Farinas AJ, et al. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res. 2002;8(2):514–9.PubMed

13.

Liu L, Yoon JH, Dammann R, Pfeifer GP. Frequent hypermethylation of the RASSF1A gene in prostate cancer. Oncogene. 2002;21(44):6835–40. doi:10.1038/sj.onc.1205814.PubMedCrossRef

14.

Woodson K, Hanson J, Tangrea J. A survey of gene-specific methylation in human prostate cancer among black and white men. Cancer Lett. 2004;205(2):181–8. doi:10.1016/j.canlet.2003.11.027.PubMedCrossRef

15.

Singal R, Ferdinand L, Reis IM, Schlesselman JJ. Methylation of multiple genes in prostate cancer and the relationship with clinicopathological features of disease. Oncol Rep. 2004;12(3):631–7.PubMed

16.

Florl AR, Steinhoff C, Muller M, Seifert HH, Hader C, Engers R, et al. Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation. Br J Cancer. 2004;91(5):985–94. doi:10.1038/sj.bjc.6602030.PubMedCentralPubMed

17.

Jeronimo C, Henrique R, Hoque MO, Mambo E, Ribeiro FR, Varzim G, et al. A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res. 2004;10(24):8472–8. doi:10.1158/1078-0432.CCR-04-0894.PubMedCrossRef

18.

Bastian PJ, Ellinger J, Wellmann A, Wernert N, Heukamp LC, Muller SC, et al. Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci. Clin Cancer Res. 2005;11(11):4097–106. doi:10.1158/1078-0432.CCR-04-1832.PubMedCrossRef

19.

Hoque MO, Topaloglu O, Begum S, Henrique R, Rosenbaum E, Van Criekinge W, et al. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J Clin Oncol. 2005;23(27):6569–75. doi:10.1200/JCO.2005.07.009.PubMedCrossRef

20.

Cho NY, Kim BH, Choi M, Yoo EJ, Moon KC, Cho YM, et al. Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features. J Pathol. 2007;211(3):269–77. doi:10.1002/path.2106.PubMedCrossRef

21.

Roupret M, Hupertan V, Yates DR, Catto JW, Rehman I, Meuth M, et al. Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage. Clin Cancer Res. 2007;13(6):1720–5. doi:10.1158/1078-0432.CCR-06-2467.PubMedCrossRef

22.

Kawamoto K, Okino ST, Place RF, Urakami S, Hirata H, Kikuno N, et al. Epigenetic modifications of RASSF1A gene through chromatin remodeling in prostate cancer. Clin Cancer Res. 2007;13(9):2541–8. doi:10.1158/1078-0432.CCR-06-2225.PubMedCrossRef

23.

Henrique R, Ribeiro FR, Fonseca D, Hoque MO, Carvalho AL, Costa VL, et al. High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients. Clin Cancer Res. 2007;13(20):6122–9. doi:10.1158/1078-0432.CCR-07-1042.PubMedCrossRef

24.

Roupret M, Hupertan V, Catto JW, Yates DR, Rehman I, Proctor LM, et al. Promoter hypermethylation in circulating blood cells identifies prostate cancer progression. Int J Cancer. 2008;122(4):952–6. doi:10.1002/ijc.23196.PubMedCrossRef

25.

Syeed N, Syed Sameer A, Hamid A, Shah ZA, Afroze D, Rasool R, et al. Promoter methylation profile of GSTP1 and RASSF1A in benign hyperplasia and metastatic prostate cancer patients in a Kashmiri population. Mol Med Rep. 2010;3(5):883–7. doi:10.3892/mmr.2010.348.PubMed

26.

Liu L, Kron KJ, Pethe VV, Demetrashvili N, Nesbitt ME, Trachtenberg J, et al. Association of tissue promoter methylation levels of APC, TGFbeta2, HOXD3 and RASSF1A with prostate cancer progression. Int J Cancer. 2011;129(10):2454–62. doi:10.1002/ijc.25908.PubMedCrossRef

27.

Vasiljevic N, Wu K, Brentnall AR, Kim DC, Thorat MA, Kudahetti SC, et al. Absolute quantitation of DNA methylation of 28 candidate genes in prostate cancer using pyrosequencing. Dis Markers. 2011;30(4):151–61. doi:10.3233/DMA-2011-0790.PubMedCrossRef

28.

Dimitriadis E, Kalogeropoulos T, Velaeti S, Sotiriou S, Vassiliou E, Fasoulis L, et al. Study of genetic and epigenetic alterations in urine samples as diagnostic markers for prostate cancer. Anticancer Res. 2013;33(1):191–7.PubMed

29.

Yaqinuddin A, Qureshi SA, Pervez S, Bashir MU, Nazir R, Abbas F. Frequent DNA hypermethylation at the RASSF1A and APC gene loci in prostate cancer patients of Pakistani origin. ISRN Urol. 2013;2013:627249. doi:10.1155/2013/627249.PubMedCentralPubMed

30.

Divyya S, Naushad SM, Murthy PV, Reddy CR, Kutala VK. GCPII modulates oxidative stress and prostate cancer susceptibility through changes in methylation of RASSF1, BNIP3, GSTP1 and Ec-SOD. Mol Biol Rep. 2013. doi:10.1007/s11033-013-2655-7.

31.

Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC, et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res. 2004;64(6):1975–86.PubMedCrossRef

32.

Prior C, Guillen-Grima F, Robles JE, Rosell D, Fernandez-Montero JM, Agirre X, et al. Use of a combination of biomarkers in serum and urine to improve detection of prostate cancer. World J Urol. 2010;28(6):681–6. doi:10.1007/s00345-010-0583-x.PubMedCrossRef

33.

Padar A, Sathyanarayana UG, Suzuki M, Maruyama R, Hsieh JT, Frenkel EP, et al. Inactivation of cyclin D2 gene in prostate cancers by aberrant promoter methylation. Clin Cancer Res. 2003;9(13):4730–4.PubMed

34.

Kang GH, Lee S, Lee HJ, Hwang KS. Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia. J Pathol. 2004;202(2):233–40. doi:10.1002/path.1503.PubMedCrossRef

35.

Woodson K, Gillespie J, Hanson J, Emmert-Buck M, Phillips JM, Linehan WM, et al. Heterogeneous gene methylation patterns among pre-invasive and cancerous lesions of the prostate: a histopathologic study of whole mount prostate specimens. Prostate. 2004;60(1):25–31. doi:10.1002/pros.20013.PubMedCrossRef

36.

Bastian PJ, Palapattu GS, Yegnasubramanian S, Rogers CG, Lin X, Mangold LA, et al. CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer. J Urol. 2008;179(2):529–34. doi:10.1016/j.juro.2007.09.038. discussion 34–5.PubMedCentralPubMedCrossRef

37.

Pan J, Chen J, Zhang B, Chen X, Huang B, Zhuang J, et al. Association between RASSF1A promoter methylation and prostate cancer: a systematic review and meta-analysis. PLoS One. 2013;8(9):e75283. doi:10.1371/journal.pone.0075283.PubMedCentralPubMedCrossRef

38.

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60. doi:10.1136/bmj.327.7414.557.PubMedCentralPubMedCrossRef

39.

Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719–48.PubMed

40.

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.PubMedCrossRef

41.

Thakkinstian A, McElduff P, D'Este C, Duffy D, Attia J. A method for meta-analysis of molecular association studies. Stat Med. 2005;24(9):1291–306. doi:10.1002/sim.2010.PubMedCrossRef

42.

Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–101.PubMedCrossRef

43.

Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.PubMedCentralPubMedCrossRef

44.

Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.PubMedCentralPubMedCrossRef

45.

Dammann R, Schagdarsurengin U, Strunnikova M, Rastetter M, Seidel C, Liu L, et al. Epigenetic inactivation of the Ras-association domain family 1 (RASSF1A) gene and its function in human carcinogenesis. Histol Histopathol. 2003;18(2):665–77.PubMed

46.

Pfeifer GP, Dammann R. Methylation of the tumor suppressor gene RASSF1A in human tumors. Biochemistry (Mosc). 2005;70(5):576–83.PubMedCrossRef

47.

Kuzmin I, Gillespie JW, Protopopov A, Geil L, Dreijerink K, Yang Y, et al. The RASSF1A tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells. Cancer Res. 2002;62(12):3498–502.PubMed

48.

Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature. 2004;429(6990):457–63. doi:10.1038/nature02625.PubMedCrossRef

49.

Gao T, Wang S, He B, Pan Y, Song G, Gu L, et al. The association of RAS association domain family Protein1A (RASSF1A) methylation states and bladder cancer risk: a systematic review and meta-analysis. PLoS One. 2012;7(11):e48300. doi:10.1371/journal.pone.0048300.PubMedCentralPubMedCrossRef

50.

Truong M, Yang B, Jarrard DF. Toward the detection of prostate cancer in urine: a critical analysis. J Urol. 2013;189(2):422–9. doi:10.1016/j.juro.2012.04.143.PubMedCentralPubMedCrossRef

51.

Ploussard G, de la Taille A. Urine biomarkers in prostate cancer. Nat Rev Urol. 2010;7(2):101–9. doi:10.1038/nrurol.2009.261.PubMedCrossRef

Title: The association between RASSF1A promoter methylation and prostate cancer: evidence from 19 published studies
Authors: Yu-Zheng Ge
Lu-Wei Xu
Rui-Peng Jia
Zheng Xu
Yu-Ming Feng
Ran Wu
Peng Yu
Yan Zhao
Zan-Long Gui
Si-Jia Tan
Qun Song
Publication date: 01-04-2014
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 4/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-013-1515-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2014

Pyrosequencing analysis of BRCA1 methylation level in breast cancer cells

Knockdown of CD44 enhances chemosensitivity of acute myeloid leukemia cells to ADM and Ara-C

Decorin-mediated inhibition of cholangiocarcinoma cell growth and migration and promotion of apoptosis are associated with E-cadherin in vitro

Association of IL-6 polymorphisms with hepatocellular carcinoma risk: evidences from a meta-analysis

Piperine induces apoptosis of lung cancer A549 cells via p53-dependent mitochondrial signaling pathway

Study on the association between the Arg194Trp polymorphism in the XRCC1 gene and the risk of hematological malignancies

Keynote webinar | Spotlight on antibody–drug conjugates in cancer